82.62 -0.25 (-0.30%)
After hours: 5:14PM EDT
|Bid||82.62 x 900|
|Ask||83.00 x 1300|
|Day's Range||81.16 - 82.87|
|52 Week Range||66.10 - 87.35|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||23.24|
|Forward Dividend & Yield||2.20 (2.60%)|
|1y Target Est||N/A|
NewLink Genetics Corporation (NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a conditional marketing authorization for investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck & Co., Inc. (MRK). This Committee recommendation will now be reviewed by the European Commission (EC) which, if it chooses to affirm the CHMP’s recommendation, will grant a centralized marketing authorization of the vaccine (brand name ERVEBO®) under a unified label valid in 31 European countries. Should this vaccine be approved by the FDA, a monetizable Priority Review Voucher (PRV) would be issued, in which NewLink Genetics owns a substantial financial interest.
Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L
Merck (MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live). If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO® (pronounced UR-VEE-BOH) and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The CHMP’s recommendation, completed under accelerated assessment, will now be considered by the European Commission.
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 8,120,633 common shares at a price of C$0.07 per common share for gross proceeds of C$568,444.
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed on SEDAR an amendment to its management information circular dated September 23, 2019 (the "Circular") to amend the maximum share consolidation ratio from 100:1 to 300:1 (the "Amendment"). BriaCell’s Board of Directors retains the discretion to fix the ratio and determine the timing for implementation of the share consolidation. As indicated in the Circular, BriaCell is considering applying for listing on a recognized US stock exchange. The conditions to any such listing would include the common shares trading at a minimum prescribed price and would, based on current trading values, require a significant share consolidation.
Merck (MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report. The report highlights the company’s performance and progress in its four corporate responsibility priority areas of Access to Health, Employees, Environmental Sustainability and Ethics & Values. “Operating responsibly is at the heart of our ability to deliver sustainable impact and long-term value for our business and society,” said Kenneth C. Frazier, Merck chairman and chief executive officer.
Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it from fighting and destroying cancer cells. Bria-IMT™ activates the immune system to fight and eliminate the cancer cells.
KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China
Merck (MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental NDA (sNDA) for a new indication for use of DIFICID tablets and oral suspension for the treatment of Clostridium (also known as Clostridioides) difficile infections (CDI) in children aged six months or older. Both applications have received a priority review classification by the FDA.
Merck (MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 29. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.
BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage.
Merck and AstraZeneca’s LYNPARZA Reduced the Risk of Disease Progression or Death by 51% in Men with Homologous Recombination Repair Gene Mutations First Positive Phase 3 Tri
Merck (MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, Chief Marketing Officer for Merck, is scheduled to present during a fireside chat at the Cantor Fitzgerald 2019 Annual Global Healthcare Conference in New York on Wednesday, Oct. 2, at 2:25 p.m. EDT. For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.
Merck (MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 RECARBRIO™ (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) RESTORE-IMI 2 trial met its primary endpoint. The global, multicenter, randomized, non-inferiority trial investigated the efficacy and safety of Merck’s antibacterial product RECARBRIO for use in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). Results from the trial showed RECARBRIO met both the primary and key secondary endpoints of statistical non-inferiority compared to piperacillin/tazobactam in Day 28 all-cause mortality and clinical response at early follow up, respectively, in the modified intent-to-treat (MITT) population.
Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium
Merck , known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, an orally available kinase inhibitor discovered by Eisai.
AstraZeneca and Merck’s LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Bas
Analyses from the Phase III JAVELIN Renal 101 study support efficacy of BAVENCIO plus axitinib across multiple subgroups of patients with advanced renal cell carcinoma (RCC) Abstracts highlight data on ...
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. Additionally, Dr. Bill Williams, BriaCell’s President & CEO, has been selected to lead the upcoming special joint issue of the prestigious, peer-reviewed journals, Frontiers in Pharmacology and Frontiers in Oncology with the research topic of 'Targeted Immunotherapy for Cancer'. Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center.
Not intended for UK-based media Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, ...
Not intended for distribution in the USA , Canada or the UK Key ESMO Abstracts # BAVENCIO ® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX ® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase ...
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company for gross proceeds of up to approximately C$600,000 at a price per common share of C$0.07. The closing of the Offering is scheduled to occur on or about September 26, 2019. All securities issued under the Private Placement will be subject to a hold period expiring 4 months plus 1 day following the closing date of the Private Placement.
Not intended for US, Canada and UK-based media Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with ...
Approvals Based on Findings from the Phase 3 DRIVE-SHIFT Trial Evaluating a Switch to DELSTRIGO
Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress. Publicly-traded securities of BriaCell Therapeutics Corp. (BCT.V) (BCTXF) will remain halted for the duration of CEO Dr. Williams’ presentation. Robust responder experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain – tumors that had metastasized to areas outside of her breasts. Prior to the Combination Study of Bria-IMT™ with KEYTRUDA®, she had failed prior regimens with 16 agents (13 chemotherapy and 3 hormonal).